文献速递血栓与止血

延长初级/次级治疗疗程以预防静脉血栓栓塞复发:一项系统评价与荟萃分析

Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis.
PubMed 文献 · Blood Adv · 2025-01-01

该荟萃分析纳入22项随机对照试验(11617例受试者),比较较短(3-6个月)与较长(>6个月)抗凝疗程用于静脉血栓栓塞(VTE)初级治疗,以及中断与无限期抗血栓治疗用于VTE次级预防的获益与危害。结果显示,初级治疗中较短疗程更有利;而无诱因VTE或慢性危险因素所致VTE的次级预防中,无限期抗血栓治疗更有利。

要点

  • 初级治疗中,较长疗程(>6个月)较大出血风险升高(RR 2.02,95%CI 1.02-3.98;高确定性)。
  • 次级预防中,无限期抗凝较中断治疗降低死亡率(RR 0.54,95%CI 0.36-0.81;高确定性)。
  • 无限期抗血小板治疗对死亡率的影响证据确定性低(RR 0.95,95%CI 0.53-1.68)。

核心结论

  • 对于所有类型VTE的初级治疗,较短(3-6个月)抗凝疗程更有利。
  • 对于无诱因VTE或慢性危险因素所致VTE的次级预防,无限期抗血栓治疗更有利。

研究设计与样本

  • 系统评价与荟萃分析,检索比较较短(3-6个月)与较长(>6个月)抗凝疗程用于VTE初级治疗、或比较中断与无限期抗血栓治疗用于VTE次级预防的随机对照试验。
  • 共纳入22项随机对照试验,11617例受试者。
  • 由两名评价者筛选合格试验并采集数据。

主要发现

  • 初级治疗中,较长疗程(>6个月)较3-6个月疗程可能降低复发性PE(RR 0.66,95%CI 0.42-1.02)和DVT(RR 0.85,95%CI 0.63-1.14),但与大出血风险升高相关(RR 2.02,95%CI 1.02-3.98;高确定性),并与死亡率升高相关(RR 1.43,95%CI 0.85-2.41;中等确定性)。
  • 次级预防中,无限期抗凝较中断治疗降低死亡率(RR 0.54,95%CI 0.36-0.81)、复发性PE(RR 0.25,95%CI 0.16-0.41)和DVT(RR 0.15,95%CI 0.10-0.21),但增加出血风险(RR 1.98,95%CI 1.18-3.30),均为高确定性。
  • 无限期抗血小板治疗可能降低死亡率(RR 0.95,95%CI 0.53-1.68;低确定性),可能降低复发性PE(RR 0.65,95%CI 0.41-1.03;中等确定性)和DVT(RR 0.44,95%CI 0.17-1.13;中等确定性),可能增加出血风险(RR 1.28,95%CI 0.48-3.41;低确定性)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antithrombotic therapy can prevent recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE). It is, however, associated with an increased risk for major bleeding. This meta-analysis systematically reviewed the evidence regarding the duration of antithrombotic therapy to assess benefits and harms. We systematically searched for randomized controlled trials (RCTs) that compared shorter (3-6 months) with longer (>6 months) courses of anticoagulation for the primary treatment of venous thromboembolism (VTE) or that compared discontinued with indefinite antithrombotic therapy for the secondary prevention of VTE. Pairs of reviewers screened the eligible trials and collected data. This study included 22 RCTs (11 617 participants). Pooled estimates showed that, for the primary treatment of unprovoked VTE, VTE provoked by chronic risk factors or transient risk factors, treating patients with a longer course (>6 months) of anticoagulation, as opposed to a shorter course (3-6 months), probably reduced recurrent PE (risk ratio [RR], 0.66; 95% confidence interval [CI], 0.42-1.02) and DVT (RR, 0.85; 95% CI, 0.63-1.14), but it was associated with increased mortality (RR, 1.43; 95% CI, 0.85-2.41) (moderate certainty) and a higher risk for major bleeding (RR, 2.02; 95% CI, 1.02-3.98; high certainty). For the secondary prevention of unprovoked VTE and VTE provoked by chronic risk factors, when compared with discontinuing treatment, indefinite anticoagulation therapy was associated with decreased mortality (RR, 0.54; 95% CI, 0.36-0.81), a reduction in recurrent PE (RR, 0.25; 95% CI, 0.16-0.41) and DVT (RR, 0.15; 95% CI, 0.10-0.21), and an increase in the risk for bleeding (RR, 1.98; 95% CI, 1.18-3.30), all supported by high certainty. Indefinite antiplatelet therapy may be associated with decreased mortality (RR, 0.95; 95% CI: 0.53-1.68; low certainty), probably a reduction in recurrent PE (RR, 0.65; 95% CI, 0.41-1.03) and DVT (RR, 0.44; 95% CI, 0.17-1.13) (moderate certainty), and may increase the risk for bleeding (RR, 1.28; 95% CI, 0.48-3.41; low certainty). In summary, for the primary treatment of all types of VTE, shorter (3-6 months) duration of anticoagulation is more beneficial. For the secondary prevention of unprovoked VTE or VTE provoked by chronic risk factors, indefinite antithrombotic treatment is more beneficial.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Li A, Khatib R, Lopes LC, et al. Duration of primary/secondary treatment to prevent recurrent venous thromboembolism: a systematic review and meta-analysis. Blood Adv. 2025. PMID: 40198201. doi:10.1182/bloodadvances.2024015371

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。